Mereo BioPharma Group (MREO) to Release Quarterly Earnings on Wednesday

Mereo BioPharma Group (NASDAQ:MREO) will likely be announcing its earnings results before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of $0.02 per share for the quarter.

Mereo BioPharma Group Price Performance

Shares of MREO stock opened at $2.53 on Wednesday. Mereo BioPharma Group has a 52 week low of $2.25 and a 52 week high of $5.02. The firm has a 50 day moving average of $2.86 and a two-hundred day moving average of $3.59.

Wall Street Analyst Weigh In

Several equities analysts have commented on MREO shares. Jefferies Financial Group initiated coverage on shares of Mereo BioPharma Group in a research report on Friday, December 6th. They issued a “buy” rating and a $7.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a research report on Monday, January 13th. Lifesci Capital initiated coverage on shares of Mereo BioPharma Group in a research report on Tuesday, December 24th. They set an “outperform” rating and a $10.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a research report on Tuesday. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $7.83.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.